Literature DB >> 24451298

Gemcitabine-Induced Pseudocellulitis in a Patient With Recurrent Lymphedema: A Case Report and Review of the Current Literature.

Susanna Curtis1, Simon Hong, Rasim Gucalp, Manuela Calvo.   

Abstract

Gemcitabine is a chemotherapeutic agent used for treatment of a variety of malignancies. It has been associated with multiple cutaneous reactions including rash, alopecia, and pruritus. Less commonly, gemcitabine has been associated with "pseudocellulitis," a noninfectious skin inflammatory reaction, which resembles cellulitis. The majority of cases reported in the literature are radiation recall reactions in which inflammation occurs in areas of previous radiation post drug treatment; however, there are also reports of pseudocellulitis occurring in areas of preexisting lymphedema. The pathophysiology of both of these reactions are still unknown, though it is theorized that areas of lymphedema may both increase concentration of gemcitabine and reduce its rate of metabolism leading to increased drug exposure time. In this study, we report a case of pseudocellulitis in a patient with chronic lower extremity lymphedema and a review of the current literature. By recognizing this side effect of gemcitabine, one can avoid unnecessary hospitalization and exposure to antibiotics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 24451298     DOI: 10.1097/MJT.0000000000000024

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  3 in total

1.  Gemcitabine-induced pseudocellulitis: a case report and review of the literature.

Authors:  H Bami; C Goodman; G Boldt; M Vincent
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

2.  Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma.

Authors:  Eseosa Asemota; Erika Reid; Carrie Kovarik
Journal:  JAAD Case Rep       Date:  2015-06-08

3.  Gemcitabine-associated acute lipodermatosclerosislike eruption: An underrecognized phenomenon.

Authors:  Amit Mittal; Jonathan S Leventhal
Journal:  JAAD Case Rep       Date:  2017-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.